Shanti Jampani, MD
Child & Adolescent Psychiatry · Roseville, CANPI 1174835433
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,341, more than ten times the $36 reported in 2022. Among child & adolescent psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tris Pharma Inc$432
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$253
- Neurocrine Biosciences, Inc.$238
- Axsome Therapeutics, Inc.$182
- Otsuka America Pharmaceutical, Inc.$181
- Bausch Health US, LLC$159
- plus $944 from 12 others
What the payments were for
- Food & beverage$2,389100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tris Pharma Inc | 27 | $432 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $253 |
| Neurocrine Biosciences, Inc. | 11 | $238 |
| Axsome Therapeutics, Inc. | 8 | $182 |
| Otsuka America Pharmaceutical, Inc. | 8 | $181 |
| Bausch Health US, LLC | 7 | $159 |
| Teva Pharmaceuticals USA, Inc. | 5 | $138 |
| Corium, LLC | 10 | $127 |
| AbbVie | 6 | $116 |
| Lundbeck LLC | 4 | $95 |
| Johnson & Johnson | 3 | $94 |
| Almatica Pharma LLC | 3 | $89 |
| Sage Therapeutics, LLC | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| Neuronetics, Inc. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Alkermes, Inc. | 1 | $22 |
How this compares
$2,389 in reported general payments places this provider in the 90th percentile of 434 child & adolescent psychiatry providers in California.
See all child & adolescent psychiatry providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 11 | $7,612 |
| BelsomraSuvorexant | 11 | $4,947 |
| Aripiprazole | 14 | $479 |
| Bupropion XlBupropion Hcl | 28 | $397 |
| Duloxetine Hcl | 15 | $342 |
| Escitalopram Oxalate | 20 | $306 |
| Clonazepam | 56 | $291 |
| Buspirone Hcl | 23 | $237 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $231 |
| Gabapentin | 11 | $147 |
| Trazodone Hcl | 17 | $142 |
| Sertraline Hcl | 19 | $137 |
| Fluoxetine Hcl | 17 | $134 |
| Alprazolam | 17 | $106 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $73 | $7,61211 claims |
| Almatica Pharma LLCSertraline Hcl | $89 | $13719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 434 child & adolescent psychiatry providers in California.
Other child & adolescent psychiatry in Roseville
- Lorerky Ramirez-MoyaRoseville$2K
- Kevin CoxOjai$2.9M
- Sukhjit BrarFresno$283K
- Manpreet SinghSacramento$104K
- Ihab SolimanCorona del Mar$93K
- Syed NaqviLos Angeles$69K
- Ellen HeynemanSan Diego$62K
- Mark McDonaldLos Angeles$31K
- James HartmanDanville$21K
- Mohsin KhaliqueSan Ramon$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.